The mutation frequency was 82% in LDLR, 9% in APOB, and very rare in PCSK9. The study concluded that the epidemiological investigation of FH was not large-scale, FH recognition remained rudimentary, and guidelines for diagnosis and management of FH patients were incomplete in China (Peng et al., 2019). The gene discussed is PCSK9; the disease is familial hyperaldosteronism.